Higher Tumor Mutational Burden Predicts Higher Likelihood Of Lung Cancer Response To Immunotherapy Combination, Research Indicates.

MedPage Today (2/26, Bankhead) reports that research indicated “a higher tumor mutational burden (TMB) predicted a higher likelihood of lung cancer response to an immunotherapy combination, irrespective of PD-L1 expression status.” Researchers found that...